Unitaid Invests US$22 Million to Advance Access to Lenacapavir for HIV Prevention
In the lead-up to World AIDS Day, Unitaid has announced a significant US$22 million investment to fast-track the introduction and access to lenacapavir, a revolutionary long-acting option for HIV prevention.
This initiative includes pathfinder projects in South Africa and Brazil, spearheaded by Wits RHI and Fiotec, to integrate lenacapavir into a comprehensive range of pre-exposure prophylaxis (PrEP) options. The program is designed to meet the specific needs of adolescent girls and young women, men who have sex with men, and transgender and non-binary individuals—populations at heightened risk of HIV.
Unitaid’s efforts aim to support the rapid and scalable adoption of lenacapavir as it receives regulatory approvals for widespread use.
